Enanta Pharmaceuticals (ENTA) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Indaptus Therapeutics (INDP) over the past year, gaining 11.6% versus a loss of 38.8%. Over five years, ENTA leads with a -82.7% price change compared with -99.0% for INDP. Enanta Pharmaceuticals is the larger company by market cap ($360.3 million vs $301.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | INDP |
|---|---|---|
| Share price | $12.37 | $2.26 |
| Market cap | $360.28M | $301.13M |
| 1-day change | +1.64% | -12.74% |
| YTD return | -21.56% | -22.34% |
| 1-year return | +11.64% | -38.75% |
| 5-year return | -82.69% | -98.97% |
| EPS (TTM) | $-2.42 | $-6.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.15 | $5.96 |
| 52-week low | $10.20 | $0.92 |
| Distance from 52-week high | -27.87% | -62.08% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +76.48% | — |
| Average volume | 226.58K | 829.14K |
| Shares outstanding | 29.13M | 133.24M |
| Employees | 120 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed INDP by 50.4 percentage points over the past year.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ENTA vs INDP FAQ
Which is bigger, Enanta Pharmaceuticals or Indaptus Therapeutics?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $360.28M compared with $301.13M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, ENTA or INDP?
ENTA returned +11.64% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.